Abstract:Metformin, a widely used antidiabetic drug, possesses other beneficial activities, including cardiovascular protection, anti-tumorigenesis, antiaging, and weight control. This Cutting-Edge Research Highlights outlines some latest basic research discoveries on metformin’s suppression of mitochondrial electron transport chain (METC) in the intervention of pulmonary inflammatory disorders, including tuberculosis and acute respiratory distress syndrome in animal models. These novel discoveries further support metformin as a pleiotropic drug for treating diverse diseases. (First online: February 19, 2023) REFERENCES Foretz M, Guigas B, Bertrand L, Pollak M, Viollet B. Metformin: from mechanisms of action to therapies. Cell Metab 2014; 20(6):953–66. doi: https://dx.doi.org/10.1016/j.cmet.2014.09.018 Vasan K, Werner M, Chandel NS. Mitochondrial metabolism as a target for cancer therapy. Cell Metab 2020; 32(3):341–52. doi: https://dx.doi.org/10.1016/j.cmet.2020.06.019 Kulkarni AS, Gubbi S, Barzilai N. Benefits of metformin in attenuating the hallmarks of aging. Cell Metab 2020; 32(1):15–30. doi: https://dx.doi.org/10.1016/j.cmet.2020.04.001 Day EA, Ford RJ, Smith BK, Mohammadi-Shemirani P, Morrow MR, Gutgesell RM, et al. Metformin-induced increases in GDF15 are important for suppressing appetite and promoting weight loss. Nat Metab 2019; 1(12):1202–8. doi: https://dx.doi.org/10.1038/s42255-019-0146-4 Coll AP, Chen M, Taskar P, Rimmington D, Patel S, Tadross JA, et al. GDF15 mediates the effects of metformin on body weight and energy balance. Nature 2020; 578(7795):444–8. doi: https://dx.doi.org/10.1038/s41586-019-1911-y Roca FJ, Whitworth LJ, Prag HA, Murphy MP, Ramakrishnan L. Tumor necrosis factor induces pathogenic mitochondrial ROS in tuberculosis through reverse electron transport. Science 2022; 376(6600):eabh2841. doi: https://dx.doi.org/10.1126/science.abh2841 Xian H, Liu Y, Rundberg Nilsson A, Gatchalian R, Crother TR, Tourtellotte WG, et al. Metformin inhibition of mitochondrial ATP and DNA synthesis abrogates NLRP3 inflammasome activation and pulmonary inflammation. Immunity 2021; 54(7):1463–77 e11. doi: https://dx.doi.org/10.1016/j.immuni.2021.05.004 Zhong Z, Liang S, Sanchez-Lopez E, He F, Shalapour S, Lin XJ, et al. New mitochondrial DNA synthesis enables NLRP3 inflammasome activation. Nature 2018; 560(7717):198–203. doi: https://dx.doi.org/10.1038/s41586-018-0372-z Billingham LK, Stoolman JS, Vasan K, Rodriguez AE, Poor TA, Szibor M, et al. Mitochondrial electron transport chain is necessary for NLRP3 inflammasome activation. Nat Immunol 2022; 23(5):692–704. doi: https://dx.doi.org/10.1038/s41590-022-01185-3 Guo H, Wang Q, Ghneim K, Wang L, Rampanelli E, Holley-Guthrie E, et al. Multi-omics analyses reveal that HIV-1 alters CD4+ T cell immunometabolism to fuel virus replication. Nat Immunol 2021; 22(4):423–33. doi: https://dx.doi.org/10.1038/s41590-021-00898-1

Effect of Metformin on systemic chemokine responses during anti-tuberculosis chemotherapy

Metformin increases natural killer cell functions in head and neck squamous cell carcinoma through CXCL1 inhibition

Metformin modulates corticosteroids hormones in adrenals cells promoting Mycobacterium tuberculosis elimination in human macrophages

Metformin Adjunctive Therapy Does Not Improve the Sterilizing Activity of the First-Line Antitubercular Regimen in Mice

Metformin reduces the relapse rate of tuberculosis patients with diabetes mellitus: experiences from 3-year follow-up

Quantitative Systems Pharmacology Modeling Framework of Autophagy in Tuberculosis: Application to Adjunctive Metformin Host-Directed Therapy

Distinct TB-antigen stimulated cytokine profiles as predictive biomarkers for unfavorable treatment outcomes in pulmonary tuberculosis

Cytokine and chemokine profiles in pulmonary tuberculosis with pre-diabetes

Metformin, a “Wonder Drug”, Targets METC for Pulmonary Protection

Toxicity associated with tuberculosis chemotherapy in the REMoxTB study

Clostridium, Bacteroides and Prevotella Associates with Increased Fecal Metabolites Trans-4-Hydroxy-L-proline and Genistein in Active Pulmonary Tuberculosis Patients During Anti-Tuberculosis Chemotherapy with Isoniazid-Rifampin-pyrazinamide-ethambutol (HRZE)

Metformin reduces the risk of poor treatment outcomes among individuals with rifampicin-resistant tuberculosis and type-2 diabetes mellitus

Metformin effect on gut microbiota: insights for HIV-related inflammation

Metformin's dual impact on Gut microbiota and cardiovascular health: A comprehensive analysis

Metformin Enhances Antibody-Mediated Recognition of HIV-Infected CD4 T-Cells by Decreasing Viral Release

Tumor-Suppressive Effect of Metformin via the Regulation of M2 Macrophages and Myeloid-Derived Suppressor Cells in the Tumor Microenvironment of Colorectal Cancer

How does metformin act as a host-directed agent in tuberculosis associated with diabetes mellitus?

Metformin as adjuvant treatment in hepatitis C virus infections and associated complications

Metformin may be a viable adjunctive therapeutic option to potentially enhance immune reconstitution in HIV-positive immunological non-responders

Harnessing Metformin's Immunomodulatory Effects on Immune Cells to Combat Breast Cancer

Gastrointestinal microbiota composition predicts peripheral inflammatory state during treatment of human tuberculosis